Pfizer starts mid-stage trial for vaccine against omicron subvariant

The vaccine targets both the original as well as the BA.2 omicron subvariant

Reuters
Published : 27 July 2022, 12:07 PM
Updated : 27 July 2022, 12:07 PM

Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified COVID-19 vaccine which targets both the original as well as the BA.2 omicron subvariant.

Pfizer said the vaccine is in an initial proof-of-concept study to gather more data.

Together, the BA.4 and BA.5 subvariants are estimated to make up nearly 95% of the circulating coronavirus variants in the United States for the week ended Jul 23.

Toufique Imrose Khalidi
Editor-in-Chief and Publisher